米索硝唑和SR-2508对C3H/He小鼠乳腺肿瘤的放射增敏作用研究。

Studies in radiosensitizing effects of misonidazole and SR-2508 on C3H/He mouse mammary tumors.

作者信息

Ono K, Takahashi M, Nishidai T, Dodo Y, Shibamoto Y, Hiraoka M, Yukawa Y, Abe M

出版信息

Radiat Med. 1984 Jan-Mar;2(1):71-5.

Abstract

The radiosensitizing efficacy of SR-2508, a new 2-nitroimidazole, which is less neurotoxic than misonidazole (MISO) was studied using transplantable mammary carcinoma of C3H/He mice. Tumor responses to treatments were evaluated by growth-delay time assay. In single irradiations, the enhancement ratios of 0.5 mmole/kg of MISO and 1.5 mmole/kg of SR-2508, which were equitoxic to C3H/He mice, were 1.42 and 1.84 respectively. In fractionated irradiations with three fractions over two days or five fractions over four days, the enhancement ratios of 1.5 mmole/kg of SR-2508 were 1.40 and 1.34 respectively. On the other hand the enhancement ratios of MISO at the above mentioned dose in respective fractionated irradiations were 1.15 or 1.11. SR-2508 is considered promising as a hypoxic cell radiosensitizer for clinical use.

摘要

使用C3H/He小鼠的可移植性乳腺癌，对一种新的2-硝基咪唑SR-2508的放射增敏效果进行了研究，该物质的神经毒性比米索硝唑（MISO）小。通过生长延迟时间测定评估肿瘤对治疗的反应。在单次照射中，对C3H/He小鼠具有同等毒性的0.5毫摩尔/千克MISO和1.5毫摩尔/千克SR-2508的增强比分别为1.42和1.84。在两天内分三次照射或四天内分五次照射中，1.5毫摩尔/千克SR-2508的增强比分别为1.40和1.34。另一方面，在相应的分次照射中，上述剂量的MISO的增强比为1.15或1.11。SR-2508被认为有望作为一种用于临床的低氧细胞放射增敏剂。